Home » Market News » DirectorsTalk Highlights » CORRECTION: Clarification Regarding Medusa 19 Antibody Test
Avacta Group Plc

CORRECTION: Clarification Regarding Medusa 19 Antibody Test

DirectorsTalk would like to highlight that the article from TheBusinessdesk.com has now been deleted and DirectorsTalk would also like to mention that Avacta is not involved in the antibody test produced by Medusa 19.

Avacta Group plc a the developer of Affimer® biotherapeutics and reagents, has issued a clarification following information appearing on the Medusa 19 web site regarding a SARS-CoV-2 antibody test on Friday, 14 August 2020.

Avacta is not involved with Medusa 19’s development of the antibody test.  Performance figures appearing on Medusa 19’s web site on Friday, 14 August 2020 relate to this antibody test and do not relate to Avacta’s rapid SARS-CoV-2 antigen test.

Avacta will update the market on continued progress and on the performance of its antigen test when appropriate.

Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.